Who are XORTX Therapeutics Inc.'s main suppliers?

XORTX Therapeutics Inc. (XRTX) key suppliers include: CONTRACT-MANUFACTURING-ORGANIZATIONS, THIRD-PARTY-CONTRACT-MANUFACTURERS, ACADEMIC-INSTITUTIONS, CLINICS, CROS and 2 more. View the full supplier network at chainsifter.com/chain/XRTX.

Who are XORTX Therapeutics Inc.'s major customers?

XORTX Therapeutics Inc. (XRTX) key customers include: Rockwell Medical, Inc., Rockwell Medical, Inc., APAC-RESOURCES-INC, BC0911882-XORTX-PHARMA-CORP, CHIEF-FINANCIAL-OFFICER-VIVO-CANNABIS-INC and 13 more. View the full customer network at chainsifter.com/chain/XRTX.

What sector is XORTX Therapeutics Inc. in?

XORTX Therapeutics Inc. (XRTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

XORTX Therapeutics Inc. Supplier List (XRTX): 7 Verified Suppliers

7Suppliers

18Customers

1Debt Items

5Related Chains

Source-Backed Evidence Depth

XORTX Therapeutics Inc. (XRTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships

1Distinct source URLs

9High confidence

0.722Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

XORTX Therapeutics Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS	CONTRACT-MANUFACTURING-ORGANIZATIONS	92%	We do not control the operational processes of the contract manufacturing organizations with whom we contract, and we are dependent on these third parties to produce our product candidates in accorda…
THIRD-PARTY-CONTRACT-MANUFACTURERS	THIRD-PARTY-CONTRACT-MANUFACTURERS	92%	We currently rely on a limited number of third-party contract manufacturers for all the required raw materials for our preclinical research and clinical trials, as well as for the manufacture of our …
ACADEMIC-INSTITUTIONS	ACADEMIC-INSTITUTIONS	90%	We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee precli…
CLINICS	CLINICS	90%	We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee precli…
CROS	CROS	90%	We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee precli…
HOSPITALS	HOSPITALS	90%	We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee precli…
OTHER-THIRD-PARTY-STRATEGIC-PARTNERS	OTHER-THIRD-PARTY-STRATEGIC-PARTNERS	90%	We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee precli…

XORTX Therapeutics Inc. Customers

Ticker	Name	Confidence	Evidence
RMTI	Rockwell Medical, Inc.	72%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
RMTI	Rockwell Medical, Inc.	72%	Reciprocal relationship from RMTI graph: Reciprocal relationship from XRTX graph: Reciprocal relationship from RMTI graph: Reciprocal relationship from XRTX graph: ion (2015). Medical degree from Uni…
APAC-RESOURCES-INC	APAC-RESOURCES-INC	62%	e or diabetic nephropathy, and patent applications filed in the U.S., EU and under the Patent Cooperation Treaty with similar claims for the treatment of metabolic syndrome, diabetes, fatty liver dis…
BC0911882-XORTX-PHARMA-CORP	BC0911882-XORTX-PHARMA-CORP	62%	e or diabetic nephropathy, and patent applications filed in the U.S., EU and under the Patent Cooperation Treaty with similar claims for the treatment of metabolic syndrome, diabetes, fatty liver dis…
CHIEF-FINANCIAL-OFFICER-VIVO-CANNABIS-INC	CHIEF-FINANCIAL-OFFICER-VIVO-CANNABIS-INC	62%	some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, …
CHIEF-MEDICAL-OFFICER-ROCKWELL-MEDICAL-INC	CHIEF-MEDICAL-OFFICER-ROCKWELL-MEDICAL-INC	62%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
CHIEF-MEDICAL-OFFICER-SAVARA-INC	CHIEF-MEDICAL-OFFICER-SAVARA-INC	62%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
DEFINIUM-THERAPEUTICS-INC	DEFINIUM-THERAPEUTICS-INC	62%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
DFTX	Definium Therapeutics, Inc.	62%	Reciprocal relationship from DFTX graph: Reciprocal relationship from XRTX graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from XRTX graph: Reciprocal relationship from DFTX g…
DIRECTOR-CONAVI-MEDICAL-INC	DIRECTOR-CONAVI-MEDICAL-INC	62%	some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, …
FLORIDA-RESEARCH-FOUNDATION-INC	FLORIDA-RESEARCH-FOUNDATION-INC	62%	ancial statements of changes in such judgments and estimates in future periods could be material. These judgments and estimates are based on historical experience, current and future economic conditi…
FORMER-DIRECTOR-ONCOQUEST-INC	FORMER-DIRECTOR-ONCOQUEST-INC	62%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
OTSUKA-PHARMACEUTICALS-CO-LTD	OTSUKA-PHARMACEUTICALS-CO-LTD	62%	ogy is based upon proprietary formulations of oxypurinol that improve oral bioavailability. Increased bioavailability improve the drugs ability to address the therapeutic range and utility. Manufactu…
PREVAIL-INFOWORKS-INC	PREVAIL-INFOWORKS-INC	62%	ancial statements of changes in such judgments and estimates in future periods could be material. These judgments and estimates are based on historical experience, current and future economic conditi…
QUEST-PHARMATECH-INC	QUEST-PHARMATECH-INC	62%	ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 Director December 20, 2021 Current Princip…
STEM-CELL-THERAPEUTICS-INC	STEM-CELL-THERAPEUTICS-INC	62%	some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, …
VECTUS-BIOSYSTEMS-LIMITED	VECTUS-BIOSYSTEMS-LIMITED	62%	e or diabetic nephropathy, and patent applications filed in the U.S., EU and under the Patent Cooperation Treaty with similar claims for the treatment of metabolic syndrome, diabetes, fatty liver dis…
XORTX-PHARMA-CORP	XORTX-PHARMA-CORP	62%	some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, …

XORTX Therapeutics Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
XRTX-DEBT	Debt stack $15,056	90%	Market cache reports total debt of $15,056.

XORTX Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for XORTX Therapeutics Inc..

XORTX Therapeutics Inc. Ownership

Holder	Name	Confidence	Evidence
XRTX-OWNER-TD-WATERHOUSE-CANADA-INC	TD Waterhouse Canada Inc.	90%	13F overlay lists TD Waterhouse Canada Inc. as top holder; 1 tracked holders.

XORTX Therapeutics Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
DFTX	Definium Therapeutics, Inc.	100.00	1	['customer']
DAVITA	DAVITA	100.00	2
ORANY	ORANGE	50.00	2
TNXP	Tonix Pharmaceuticals Holding Corp.	50.00	2
RMTI	Rockwell Medical, Inc.	38.88	1	['customer']

XORTX Therapeutics Inc. Supply Chain